Loading…
Chinese maker of zirconia and other ceramic dental-restoration materials for CAD/CAM dental labs.
Chinese maker of zirconia and other ceramic dental-restoration materials for CAD/CAM dental labs.
Zirconia blocks are consumables milled into crowns and bridges, so sales recur with the number of restorations. The shift of dental labs from hand-made to digitally milled work expands the market for such blocks.
In one line: A Chinese Ivoclar/3M dental-ceramics supplier.
Moat: narrow (process know-how, brand). Ceramic material formulation know-how differentiates strength/aesthetics for dental labs.
Headquarters: Qinhuangdao, Hebei, China · Employees: 1,303
Size Aidite (Qinhuangdao) Technology (301580.SZ) is a China Health Care company (Medical Specialties) with a market value of $919M, the 2470th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥41.07 on 6 Nov 2026.
Performance Over six months the shares fell 20.4%, against -16.6% for the median peer and -16.4% for the China market (cap-weighted) — 8th lowest of 21 in its peer set.
Growth Revenue grew 16.5% over the last twelve months (peer median +5.4%); the operating margin is 17.8% (peer median 10.2%).
Valuation It trades at 27.1× forward earnings against a peer median of 23.5× (7th most expensive of 18).
Price implies For today's price to make sense, revenue must grow about 20% a year for seven years (Req g). Recent delivered growth is +23%, so the hurdle is -3 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 7.9 points above its cost of capital (11.5% WACC).
Next results Next results expected around 5 May 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥1.16B | CN¥1.03B | CN¥884M | CN¥774M | CN¥601M |
| Revenue growth | — | +16% | +14% | +29% | — |
| Gross profit | CN¥628M | CN¥503M | CN¥441M | CN¥367M | CN¥265M |
| EBITDA | n/a | CN¥212M | CN¥190M | CN¥157M | CN¥108M |
| Net income | CN¥202M | CN¥196M | CN¥150M | CN¥147M | CN¥116M |
| Free cash flow | CN¥114M | CN¥219M | CN¥68.1M | CN¥118M | CN¥179M |
| Capital expenditure | CN¥123M | CN¥68.8M | CN¥84.4M | CN¥33.2M | CN¥44.5M |
| Total debt | CN¥29.3M | CN¥28.7M | CN¥7.06M | CN¥1.40M | CN¥44.3M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Aidite (Qinhuangdao) Technology 301580.SZ | $919M | -20% | +17% | 18% | 27.1× | 19.9% |
| 3M MMM | $95.7B | +30% | +2% | 21% | 19.2× | 11.3% |
| DENTSPLY SIRONA XRAY | $1.89B | -14% | -1% | 5% | 7.3× | 10.2% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 301580.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -14.9% | -5.2% | 6th lowest of 21 |
| 6-month return | -20.4% | -16.6% | 8th lowest of 21 |
| Distance from 52-week high | -53.3% | -38.7% | 3rd lowest of 21 |
| Revenue growth (TTM) | +16.5% | +5.4% | 5th highest of 21 |
| Operating margin | 17.8% | 10.2% | 6th highest of 21 |
| Forward P/E | 27.1× | 23.5× | 7th most expensive of 18 |
| Growth the price implies (Req g, 7 yrs) | 19.9% | 7.1% | 5th most demanding of 17 |
| Growth delivered (Del g) | +23.3% | +11.5% | highest of 17 |
| Hurdle (Req g minus delivered) | -3.4 pp | -3.6 pp | 9th least demanding of 17 |
| ROIC minus cost of capital | +7.9 pp | +1.9 pp | 6th highest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Aidite (Qinhuangdao) Technology 301580.SZ | China | $919M | -20% | +17% | 18% | 27.1× | 19.9% | +23.3% |
| Seegene 096530.KS | South Korea | $915M | +26% | +12% | 13% | 15.9× | -3.4% | -15.9% |
| Ningbo Jansen Superconducting Technologies 688805.SS | China | $915M | -30% | +36% | 14% | n/a | 47.2% | +17.1% |
| LifeTech Scientific 1302.HK | Hong Kong | $914M | -18% | +1% | 12% | 23.5× | 13.3% | +15.5% |
| Beijing SDL Technology 002658.SZ | China | $910M | -21% | -13% | 9% | 23.6× | 18.0% | +2.9% |
| Shanghai Runda Medical Technology 603108.SS | China | $909M | -25% | -12% | -2% | 25.1× | 22.2% | -0.2% |
| Mani 7730.T | Japan | $909M | -15% | +10% | 30% | 18.4× | 1.5% | +13.9% |
| Caina Technology 301122.SZ | China | $938M | +60% | +61% | 0% | 72.0× | n/a | n/a |
| Shantou Institute of Ultrasonic Instruments 301602.SZ | China | $944M | -19% | +4% | 30% | n/a | 13.1% | +4.6% |
| Bioventus BVS | United States | $894M | +1% | +4% | 10% | 13.1× | 6.9% | +12.1% |
| Safilo SFL.MI | Italy | $890M | +24% | -4% | 9% | 16.0× | -0.5% | +4.7% |
| Cisen Pharmaceutical 603367.SS | China | $890M | -15% | -6% | 8% | 8.3× | -12.9% | -1.3% |
| Shenzhen YHLO Biotech 688575.SS | China | $950M | -20% | +3% | 12% | 37.2× | 3.1% | +12.7% |
| Kuros Biosciences KURN.SW | Switzerland | $953M | +3% | +41% | 6% | 73.8× | n/a | n/a |
| Beijing Hotgen Biotech 688068.SS | China | $966M | -38% | +8% | -94% | n/a | n/a | n/a |
| Eckert & Ziegler EUZ.DE | Germany | $969M | -7% | +4% | 25% | 17.0× | 7.2% | +12.1% |
| Modern Dental 3600.HK | Hong Kong | $871M | +19% | +12% | 22% | 8.8× | -7.0% | +11.3% |
| Xiangyu Medical 688626.SS | China | $969M | -31% | 0% | 4% | 62.1× | n/a | n/a |
| HOB Biotech 688656.SS | China | $972M | -22% | +6% | 7% | 188.9× | 40.1% | +12.4% |
| Sino Medical Sciences Technology 688108.SS | China | $868M | -35% | +22% | 19% | 69.2× | 31.0% | +9.9% |
| JINS 3046.T | Japan | $865M | -12% | +14% | 10% | 16.6× | -7.2% | +11.7% |